文献速递胸部肿瘤

Benmelstobart联合或不联合安罗替尼用于不可切除NSCLC放化疗后巩固治疗的R-ALPS随机临床试验

Benmelstobart With or Without Anlotinib After Chemoradiotherapy for Unresectable Non-Small Cell Lung Cancer: The R-ALPS Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2026-10-29

这项在中国42个中心开展的双盲3期随机临床试验纳入553例不可切除III期NSCLC放化疗后无进展患者,评估Benmelstobart联合或不联合安罗替尼对比安慰剂巩固治疗的疗效与安全性。主要终点IRC评估PFS在联合组为15.1个月、单药组9.7个月、安慰剂组4.2个月,联合组和单药组均显著优于安慰剂。联合安罗替尼较单药未显著改善PFS,且增加严重及致死性治疗相关不良事件。

要点

  • Benmelstobart联合或不联合安罗替尼较安慰剂显著改善不可切除III期NSCLC放化疗后PFS。
  • 联合安罗替尼组3-5级治疗相关不良事件发生率48.8%,5级事件7.2%。

核心结论

  • Benmelstobart联合或不联合安罗替尼均较安慰剂显著改善不可切除III期NSCLC放化疗后PFS。
  • 联合安罗替尼较Benmelstobart单药未显著改善PFS,且增加严重和致死性治疗相关不良事件。

研究设计与样本

  • 多中心双盲3期随机临床试验,中国42个中心,2020至2023年入组。
  • 纳入不可切除III期NSCLC同步或序贯放化疗后无进展患者,共553例,中位年龄62岁,男性495例(89.5%)。
  • 第1阶段390例按1:1:1随机至Benmelstobart联合安罗替尼、Benmelstobart联合安罗替尼安慰剂或匹配安慰剂;第2阶段163例按1:1随机至两个活性方案。
  • 主要终点为独立评审委员会(IRC)评估的PFS。

主要发现

  • 第1阶段中位PFS:联合组15.1个月(95%CI 9.4-21.7),单药组9.7个月(95%CI 6.0-34.4),安慰剂组4.2个月(95%CI 3.2-6.8)。
  • 联合组对比安慰剂HR 0.49(95%CI 0.36-0.66;P<.001),单药组对比安慰剂HR 0.53(95%CI 0.39-0.72;P<.001)。
  • 第1和第2阶段汇总分析中位PFS:联合组17.4个月(95%CI 12.5-24.8),单药组11.2个月(95%CI 7.0-20.7),HR 0.82(95%CI 0.63-1.08;P=.12)。
  • 3-5级治疗相关不良事件发生率:联合组48.8%、单药组29.4%、安慰剂组19.7%;5级事件分别为7.2%、1.4%、1.5%。

临床怎么用

  • 对于不可切除III期NSCLC放化疗后无进展患者,Benmelstobart巩固治疗较安慰剂显著改善PFS。
  • 联合安罗替尼未显著改善PFS且增加严重和致死性不良事件,需权衡毒性风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Consolidation immunotherapy improves outcomes after chemoradiotherapy for unresectable stage III non-small cell lung cancer (NSCLC). Disease progression remains common, and more effective consolidation strategies are needed. OBJECTIVE: To evaluate the efficacy and safety of benmelstobart with or without anlotinib as consolidation therapy after chemoradiotherapy for unresectable stage III NSCLC. DESIGN, SETTING, AND PARTICIPANTS: This multicenter double-blind phase 3 randomized clinical trial took place at 42 centers in China from 2020 to 2023 among patients with unresectable stage III NSCLC without progression after concurrent or sequential chemoradiotherapy. In stage 1, patients were randomized 1:1:1 to 2 active regimens or placebo; in stage 2, additional patients were randomized 1:1 between the active regimens to power their direct comparison. Data cutoffs were November 30, 2023, for stage 1 and July 8, 2024, for the pooled analysis. Data analysis was performed from January 17 to March 23, 2025. INTERVENTIONS: Patients were randomized to receive benmelstobart plus anlotinib, benmelstobart plus anlotinib placebo, or their matching placebos. MAIN OUTCOMES AND MEASURES: Primary end point was independent review committee (IRC)-assessed progression-free survival (PFS). RESULTS: Of 553 participants (median [IQR] age, 62 [56-67] years; 495 male individuals [89.5%]), 390 were randomized in stage 1 and 163 in stage 2. In stage 1, median PFS was 15.1 months (95% CI, 9.4-21.7) with benmelstobart plus anlotinib, 9.7 months (95% CI, 6.0-34.4) with benmelstobart alone, and 4.2 months (95% CI, 3.2-6.8) with placebo. The hazard ratios (HRs) were 0.49 (95% CI, 0.36-0.66; P < .001) for benmelstobart plus anlotinib vs placebo and 0.53 (95% CI, 0.39-0.72; P < .001) for benmelstobart vs placebo. In the pooled stage 1 and 2 analysis, median PFS was 17.4 (95% CI, 12.5-24.8) months with benmelstobart plus anlotinib and 11.2 (95% CI, 7.0-20.7) months with benmelstobart alone (HR, 0.82; 95% CI, 0.63-1.08; P = .12). Grade 3 to 5 treatment-related adverse events occurred in 48.8%, 29.4%, and 19.7% in the benmelstobart plus anlotinib, benmelstobart alone, and placebo groups, respectively; grade 5 events occurred in 7.2%, 1.4%, and 1.5%, respectively. CONCLUSIONS AND RELEVANCE: This randomized clinical trial found that benmelstobart with or without anlotinib significantly improved PFS compared with placebo. Adding anlotinib did not significantly improve PFS compared with benmelstobart alone and increased severe and fatal treatment-related adverse events. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04325763.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Ji Y, Li Q, Chen L, et al. Benmelstobart With or Without Anlotinib After Chemoradiotherapy for Unresectable Non-Small Cell Lung Cancer: The R-ALPS Randomized Clinical Trial. JAMA Oncol. 2026. PMID: 42955021. doi:10.1001/jamaoncol.2026.3918

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。